Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of Zasocitinib in nonsegmental vitiligo
jRCT2031250527Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Nov 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zasocitinib in nonsegmental vitiligo (5 arms), sponsored by Takeda. Primary endpoint: F-VASI 75 at Week 24. Started Nov 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on jRCT2031250527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250527.